Literature DB >> 21529781

Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia II: developing imaging biomarkers to enhance treatment development for schizophrenia and related disorders.

Cameron S Carter1, Deanna M Barch, Edward Bullmore, James Breiling, Robert W Buchanan, Pamela Butler, Jonathan D Cohen, Mark Geyer, Randy Gollub, Michael F Green, Judith Jaeger, John H Krystal, Holly Moore, Keith Nuechterlein, Trevor Robbins, Steven Silverstein, Edward E Smith, Milton Strauss, Til Wykes.   

Abstract

The Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia (CNTRICS) initiative, funded by an R13 from the National Institute of Mental Health, seeks to enhance translational research in treatment development for impaired cognition in schizophrenia by developing tools from cognitive neuroscience into useful measures of treatment effects on behavior and brain function. An initial series of meetings focused on the selection of a new set of tasks from cognitive neuroscience for the measurement of treatment effects on specific cognitive and neural systems. Subsequent validation and optimization studies are underway and a subset of validated measures with well-characterized psychometric properties will be generally available in 2011. This article describes results of the first meeting of the second phase of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia, which seeks to develop imaging biomarkers and improved animal models to enhance translational research. In this meeting, we considered issues related to the use of methods such as functional magnetic resonance imaging, electroencephalography, magnetoencephalography, and transcranial magnetic simulation as biomarkers for treatment development. We explored the biological nature of the signals measured by each method, their validity and reliability as measures of cognition-related neural activity, potential confounds related to drug effects on the signal of interest, and conceptual, methodological, and pragmatic issues related to their use in preclinical, first into human, and multicenter phase II and III studies. This overview article describes the background and goals of the meeting together with a summary of the major issues discussed in more detail in the accompanying articles appearing in this issue of Biological Psychiatry.
Copyright © 2011 Society of Biological Psychiatry. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21529781      PMCID: PMC3116022          DOI: 10.1016/j.biopsych.2011.01.041

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  7 in total

1.  Endophenotypes: bridging genomic complexity and disorder heterogeneity.

Authors:  Thomas R Insel; Bruce N Cuthbert
Journal:  Biol Psychiatry       Date:  2009-12-01       Impact factor: 13.382

2.  Modafinil shifts human locus coeruleus to low-tonic, high-phasic activity during functional MRI.

Authors:  Michael J Minzenberg; Andrew J Watrous; Jong H Yoon; Stefan Ursu; Cameron S Carter
Journal:  Science       Date:  2008-12-12       Impact factor: 47.728

3.  How we say no: norepinephrine, inferior frontal gyrus, and response inhibition.

Authors:  Gary Aston-Jones; Joshua I Gold
Journal:  Biol Psychiatry       Date:  2009-04-01       Impact factor: 13.382

4.  The quest for developing new treatments from imaging techniques: promises, problems and future potential.

Authors:  Michael J Minzenberg; Cameron S Carter
Journal:  Expert Opin Drug Discov       Date:  2007-08       Impact factor: 6.098

5.  Measurement issues in the use of cognitive neuroscience tasks in drug development for impaired cognition in schizophrenia: a report of the second consensus building conference of the CNTRICS initiative.

Authors:  Deanna M Barch; Cameron S Carter
Journal:  Schizophr Bull       Date:  2008-05-21       Impact factor: 9.306

6.  Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting.

Authors:  Deanna M Barch; Cameron S Carter; Amy Arnsten; Robert W Buchanan; Jonathan D Cohen; Mark Geyer; Michael F Green; John H Krystal; Keith Nuechterlein; Trevor Robbins; Steven Silverstein; Edward E Smith; Milton Strauss; Til Wykes; Robert Heinssen
Journal:  Schizophr Bull       Date:  2008-11-20       Impact factor: 9.306

Review 7.  Applications of fMRI in translational medicine and clinical practice.

Authors:  Paul M Matthews; Garry D Honey; Edward T Bullmore
Journal:  Nat Rev Neurosci       Date:  2006-09       Impact factor: 34.870

  7 in total
  24 in total

1.  Reduced natural oscillatory frequency of frontal thalamocortical circuits in schizophrenia.

Authors:  Fabio Ferrarelli; Simone Sarasso; Yelena Guller; Brady A Riedner; Michael J Peterson; Michele Bellesi; Marcello Massimini; Bradley R Postle; Giulio Tononi
Journal:  Arch Gen Psychiatry       Date:  2012-08

Review 2.  Neuroeconomics: a bridge for translational research.

Authors:  Carla Sharp; John Monterosso; P Read Montague
Journal:  Biol Psychiatry       Date:  2012-07-15       Impact factor: 13.382

Review 3.  A review of recent literature employing electroencephalographic techniques to study the pathophysiology, phenomenology, and treatment response of schizophrenia.

Authors:  Gary Marcel Hasey; Michael Kiang
Journal:  Curr Psychiatry Rep       Date:  2013-09       Impact factor: 5.285

4.  Graph-based network analysis in schizophrenia.

Authors:  Sifis Micheloyannis
Journal:  World J Psychiatry       Date:  2012-02-22

5.  Disconnection Between Amygdala and Medial Prefrontal Cortex in Psychotic Disorders.

Authors:  Prerona Mukherjee; Amri Sabharwal; Roman Kotov; Akos Szekely; Ramin Parsey; Deanna M Barch; Aprajita Mohanty
Journal:  Schizophr Bull       Date:  2016-02-23       Impact factor: 9.306

6.  A Roadmap for the Development of Applied Computational Psychiatry.

Authors:  Martin P Paulus; Quentin J M Huys; Tiago V Maia
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2016-09

Review 7.  Investigating the mechanism(s) underlying switching between states in bipolar disorder.

Authors:  Jared W Young; Davide Dulcis
Journal:  Eur J Pharmacol       Date:  2015-03-23       Impact factor: 4.432

Review 8.  Transcranial magnetic stimulation: a neuroscientific probe of cortical function in schizophrenia.

Authors:  Shawn M McClintock; Catarina Freitas; Lindsay Oberman; Sarah H Lisanby; Alvaro Pascual-Leone
Journal:  Biol Psychiatry       Date:  2011-05-14       Impact factor: 13.382

Review 9.  Neuroimaging biomarkers for early drug development in schizophrenia.

Authors:  Jason R Tregellas
Journal:  Biol Psychiatry       Date:  2013-10-04       Impact factor: 13.382

10.  Cognitive abilities on transitive inference using a novel touchscreen technology for mice.

Authors:  J L Silverman; P T Gastrell; M N Karras; M Solomon; J N Crawley
Journal:  Cereb Cortex       Date:  2013-11-28       Impact factor: 5.357

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.